Press Releases July 15, 2026 04:05 PM

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

PacBio schedules Q2 2026 earnings call to discuss financial results on August 5, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
PACB

Pacific Biosciences (PacBio) announced it will report its second quarter 2026 financial results on August 5, 2026, and hold a conference call to discuss these results. PacBio is a life science technology company specializing in advanced sequencing solutions for genetic research across multiple sectors.

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PACB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PacBio will report Q2 2026 financial results on August 5, 2026.
  • The company offers advanced sequencing technologies used in various research fields including human genetics, plant and animal sciences, infectious diseases, and oncology.
  • The financial results call is accessible via webcast and phone for investors and analysts.

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.

Date: Wednesday, August 5, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.  

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. 

Contacts

Investors:
[email protected]

Media:
[email protected]


Risks

  • Market and financial performance could be impacted if earnings do not meet expectations.
  • As products are for research use only, regulatory changes or funding shifts in life sciences research could affect demand.
  • Technological competition and development challenges in the genetic sequencing sector may affect PacBio's market position.

More from Press Releases

FTI Consulting Expands Financial Crime Risk Management Capabilities in Australia With Appointment of Senior Managing Director Jul 15, 2026 ASP Isotopes Announces Agreements to Exchange Certain QLE Convertible Notes for ASPI Common Stock Jul 15, 2026 Figure Technology Solutions Announces Date for Second Quarter 2026 Results Jul 15, 2026 Methanex Corporation Jul 15, 2026 Record Revenue and Successful Mountain Commerce Bancorp Acquisition Drive Strong Second Quarter Results for HOMB Jul 15, 2026